Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
TG Therapeutics, Inc.
This study will evaluate the safety profile, pharmacokinetics, and efficacy of single-agent cosibelimab as well as the combination of Cosibelimab + Ublituximab + Bendamustin.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).
Measurable disease and adequate organ function as specified in the protocol
You may not be if
Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, or prior therapy with bendamustine.
Subjects receiving cancer therapy or investigational drug within 21 days of Cycle 1 Day 1.
Prior autologous stem cell transplant within 3 months
